The elephant in the GLP-1 pricing conversation: most patients regain significant weight after stopping medication. The clinical data is clear, and the financial implications are massive. Here's the math nobody wants to do.
The Regain Data
The STEP 1 extension trial showed that participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year. Similar patterns have been observed across multiple GLP-1 trials. This isn't a failure of willpower — it's biology. GLP-1 medications suppress appetite through hormonal pathways that revert when the medication stops.
For a patient who lost 30 pounds on semaglutide and stops, the expected trajectory is roughly 20 pounds regained within 12 months. That means you paid $1,188-4,188 for the initial treatment year and retained only about one-third of the benefit.
The Cost of Stop-Start Cycling
| Scenario | Year 1 | Year 2 (stopped) | Year 3 (restart) | 3-Year Total | Net Result |
|---|---|---|---|---|---|
| Continuous @ GobyMeds | $1,188 | $1,188 | $1,188 | $3,564 | Full weight loss maintained |
| Stop after Year 1, restart Year 3 | $1,188 | $0 | $1,188 + restart | $2,576+ | Regained 67%, must re-lose |
| Continuous @ Gala | $2,148 | $2,148 | $2,148 | $6,444 | Full weight loss maintained |
| Stop after Year 1, restart Year 3 | $2,148 | $0 | $2,148 + restart | $4,496+ | Regained 67%, must re-lose |
| Continuous @ brand self-pay | $3,588 | $3,588 | $3,588 | $10,764 | Full weight loss maintained |
| Stop after Year 1, restart Year 3 | $3,588 | $0 | $3,588 + restart | $7,376+ | Regained 67%, must re-lose |
The Case for Long-Term Low-Dose Maintenance
Some patients achieve their weight-loss goal and want to stop medication entirely. The data suggests a better approach: stepping down to a lower maintenance dose rather than stopping completely. Several providers support this approach with flexible dosing.
At GobyMeds' flat-rate $99/month, there's no financial incentive to reduce your dose — you pay the same at any dose. But the clinical benefit of a lower maintenance dose may be sufficient to prevent regain while reducing side effects. Discuss dose reduction (not cessation) with your provider when you approach your goal weight.
Cheapest Long-Term Maintenance Options
| Provider | Maintenance Cost | 5-Year Cost | Allows Dose Flexibility |
|---|---|---|---|
| GobyMeds | $99/mo | $5,940 | ✅ Yes |
| Oak Longevity | $130/mo | $7,800 | ✅ Yes |
| Gala GLP-1 | $179/mo | $10,740 | ✅ Yes |
| Wegovy oral (NovoCare) | $149-349/mo | $8,940-20,940 | Dose-dependent |
| Foundayo (LillyDirect) | $149-299/mo | $8,940-17,940 | Dose-dependent |
| Medicare Bridge (if eligible) | $50/mo | $3,000 | Program-dependent |
Five years of continuous GobyMeds treatment costs $5,940. Five years of stop-start cycling (1 year on, 1 year off, repeat) costs roughly $3,000 in medication but results in a net weight loss of perhaps 10-15% of what continuous treatment achieves. The continuous approach costs $2,940 more but delivers 3-6x the clinical benefit.
When Stopping Actually Makes Sense
Stopping GLP-1 medication is reasonable if you've developed intolerable side effects that don't respond to dose adjustment, you've made sustainable lifestyle changes that independently maintain your weight (rare but possible), the financial burden is genuinely unsustainable (in which case, switching to a cheaper provider like GobyMeds is usually better than stopping), or your provider recommends discontinuation for medical reasons.